Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flotetuzumab in Pediatric Relapsed or Refractory Acute Myeloid Leukemia
NCT04158739Phase 1Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jan 2020
- Primary completion
- Sep 2022
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flotetuzumab in acute myeloid leukemia (AML), sponsored by Children's Oncology Group. Primary endpoints: Dose Limiting Toxicities Due to Flotetuzumab at 29 days and Maximum Tolerated Dose or Recommended Phase 2 Dose of Flotetuzumab at 29 days. Started Jan 2020; status: active, not recruiting.
02
Drugs
flotetuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04158739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158739.